Sickle Cell Anemia: Ethics, Genetics, and Care Planning
This paper examines key ethical, genetic, and organizational considerations surrounding the treatment of sickle cell disease. It focuses on hematopoietic stem cell transplantation (HSCT) as the only known cure, discussing ethical dilemmas related to donor selection, patient eligibility, reproductive technologies, and distributive justice. The paper also reviews emerging genetic interventions such as zinc finger nucleases and cryopreservation, noting that no genetic treatment yet offers reliable cost reduction. Sections on change management and an education and communications plan address how healthcare institutions, workers, and patient advocates can respond to evolving evidence and promote equitable access to care.
- Introduction: Ethical Considerations in HSCT: Ethics of HSCT access, donor selection, and justice
- Genetics for Improving Health Outcomes: Genetic interventions, ZFNs, and cryopreservation research
- Change Management in Sickle Cell Care: Institutional response to evolving treatment evidence
- Education and Communications Plan: Outreach strategies for patients, staff, and public
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- It integrates bioethical principles (beneficence, non-maleficence, autonomy, justice) directly into the clinical discussion of HSCT, grounding abstract concepts in concrete treatment decisions.
- The paper moves logically from clinical ethics to genetic science to institutional response, giving each section a clear and distinct focus.
- The numbered education and communications plan is practical and actionable, demonstrating how healthcare workers can translate research into public outreach.
Key academic technique demonstrated
The paper demonstrates the application of ethical frameworks to a specific clinical context. Rather than discussing bioethical principles in the abstract, the author applies concepts like distributive justice and patient autonomy to real decisions — such as whether children with "less severe" sickle cell disease should receive HSCT — showing how theory shapes clinical and policy practice.
Structure breakdown
The paper is organized into four sections: an opening section on ethical considerations in HSCT; a review of genetic interventions and their current limitations; a change management section addressing how institutions should respond to new evidence; and a three-part education and communications plan targeting colleagues, patients, and the public. Each section builds on the previous one, moving from problem identification to response strategies.
Introduction: Ethical Considerations in HSCT
The only known cure for sickle cell disease is hematopoietic stem cell transplantation (HSCT). Survival rates after HSCT are high — nearly 100% — with cure rates exceeding 90% (Nickel, Hendrickson & Haight, 2014; Nickel & Kamani, 2017). To achieve the best outcomes, the donor is ideally an HLA-identical sibling. This requirement raises several ethical concerns.
The most pressing ethical concern related to HSCT is whether the procedure should be offered to children with "less severe" cases of sickle cell disease (Nickel, Hendrickson & Haight, 2014; Nickel & Kamani, 2017). Less severe cases have been defined as those without overt complications. However, Nickel, Hendrickson & Haight (2014) point out that many "less severe" cases may become more severe over time, compelling healthcare workers to consider offering HSCT to all children with sickle cell disease.
The same issue of access to HSCT extends to adult cases, patients from low-income countries, and cases where the potential recipient has "social problems" that might significantly impact health outcomes (Nickel & Kamani, 2017). Another potential ethical issue involves the deliberate use of reproductive technologies to create the HLA-identical donor (Nickel & Kamani, 2017). Healthcare workers should take care to preserve the principles of procedural and distributive justice in healthcare, while also adhering fully to the fundamental tenets of beneficence, patient autonomy, and non-maleficence. Resources for HSCT remain scarce until new research in cryobiology and cryopreservation reduces the ethical, financial, physical, and psychological burden of donor transplants.
Genetics for Improving Health Outcomes
Sickle cell disease is "characterized by a single point mutation in the seventh codon of the β-globin gene" (Hoban, Cost, Mendel, et al., 2015, p. 2597). As a genetic condition, sickle cell disease is responsive to genetic interventions, though few have been widely tested. One study demonstrates the potential efficacy of zinc finger nucleases (ZFNs) to "precisely cleave and disrupt the erythroid enhancer of the BCL11A gene" (Holmes, Reik, Rebar, et al., 2017, p. 2066). However, few studies offer promising solutions for reducing overall treatment costs, with HSCT remaining the only viable intervention.
The cultivation of specialized stem cells for treating sickle cell disease may be on the horizon. In the meantime, cryopreservation of patients' oocytes is one means of preserving fertility after treatment for the disease (Lavery, Islam, Hunt, et al., 2016). Genetic testing may also help reduce overall costs while improving public health outcomes. Predating the ZFN research conducted by Holmes, Reik, Rebar, et al. (2017), Hoban, Cost, Mendel et al. (2015) also found that "site-specific correction of the sickle mutation in hematopoietic stem cells would allow for permanent production of normal red blood cells" (p. 2597). To date, no genetic treatments for prevention or intervention have yet demonstrated reliable cost reductions.
References
Hoban, M.D., Cost, G.J., Mendel, M.C., et al. (2015). Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood, 125, 2597–2604.
Holmes, M.C., Reik, A., Rebar, E.J., et al. (2017). A potential therapy for beta-thalassemia (ST-400) and sickle cell disease. Blood, 130, 2066.
Lavery, S.A., Islam, R., Hunt, J., et al. (2016). The medical and ethical challenges of fertility preservation in teenage girls. Human Reproduction, 31(7), 1501–1507.
Nickel, R.S., Hendrickson, J.E., & Haight, A.E. (2014). The ethics of a proposed study of hematopoietic stem cell transplant for children with "less severe" sickle cell disease. Blood, 124, 861–866.
Nickel, R.S. & Kamani, N. (2017). The ethics of hematopoietic stem cell transplantation for sickle cell disease. In E. Meier, A. Abraham, & R. Fasano (Eds.), Sickle Cell Disease and Hematopoietic Stem Cell Transplantation (pp. 199–219). Springer.
Create your account
Always verify citation format against your institution’s current style guide requirements.